Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Keating

Showing results (281-290 of 436) with videos related to

Pageof 44
Sort By:
Leukemia|August 12, 2005
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemiaM Motta, L Rassenti, B J Shelvin, et al.
The American Journal of Medicine|July 1, 1993
Fludarabine therapy in Waldenström's macroglobulinemiaM A Dimopoulos, S O'Brien, H Kantarjian, et al.
Cancer|August 1, 1982
A prognostic factor analysis for use in development of predictive models for response in adult acute leukemiaM J Keating, T L Smith, E A Gehan, et al.
Cancer|July 15, 1987
Intensive treatment of acute leukemia in adults 70 years of age and olderR S Walters, H M Kantarjian, M J Keating, et al.
Cancer|April 1, 1987
Role of maintenance chemotherapy in acute promyelocytic leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Hematologic Pathology|January 1, 1987
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemiaE H Estey, M J Keating, D O Dixon, et al.
Annals of Internal Medicine|July 1, 1980
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemiaS S Legha, M J Keating, A R Zander, et al.
Acta Haematologica|January 1, 1987
Comparison of results of salvage therapy in adult acute myelogenous leukemiaM J Keating, E Estey, H M Kantarjian, et al.
Cancer|November 15, 1993
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remissionH M Kantarjian, E Estey, S O'Brien, et al.
Cancer|March 1, 1989
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Pageof 44

Showing results (281-290 of 436) with videos related to

Sort By:
Pageof 44
Leukemia|August 12, 2005
Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemiaM Motta, L Rassenti, B J Shelvin, et al.
The American Journal of Medicine|July 1, 1993
Fludarabine therapy in Waldenström's macroglobulinemiaM A Dimopoulos, S O'Brien, H Kantarjian, et al.
Cancer|August 1, 1982
A prognostic factor analysis for use in development of predictive models for response in adult acute leukemiaM J Keating, T L Smith, E A Gehan, et al.
Cancer|July 15, 1987
Intensive treatment of acute leukemia in adults 70 years of age and olderR S Walters, H M Kantarjian, M J Keating, et al.
Cancer|April 1, 1987
Role of maintenance chemotherapy in acute promyelocytic leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Hematologic Pathology|January 1, 1987
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemiaE H Estey, M J Keating, D O Dixon, et al.
Annals of Internal Medicine|July 1, 1980
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemiaS S Legha, M J Keating, A R Zander, et al.
Acta Haematologica|January 1, 1987
Comparison of results of salvage therapy in adult acute myelogenous leukemiaM J Keating, E Estey, H M Kantarjian, et al.
Cancer|November 15, 1993
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remissionH M Kantarjian, E Estey, S O'Brien, et al.
Cancer|March 1, 1989
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemiaH M Kantarjian, M J Keating, R S Walters, et al.
Pageof 44